EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Atrial fibrillation cryoablation is an effective day case treatment: the UK PolarX vs. Arctic Front Advance experience

Shohreh Honarbakhsh iD, Claire A Martin, Joao Mesquita iD, Rahul Herlekar iD, Richard Till iD, Neil T Srinivasan iD, Edward Duncan, Fong Leong iD, Rajdip Dulai iD, Rick Veasey, Sandeep Panikker iD, John Paisey iD und 8 weitere

Europace · 02.11.2023 · 25 (11)

DOI: 10.1093/europace/euad286 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Europace, online erschienen am 21.09.2023. Verfasst von Shohreh Honarbakhsh und 19 weiteren Autor:innen. Beteiligte Einrichtung: The Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS trust, W Smithfield, EC1A 7BE London, UK. Hauptthemen laut MEDLINE: Atrial Fibrillation, Cryosurgery, Pulmonary Veins, Catheter Ablation. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation for atrial fibrillation (AF). There are limited data on the PolarX Cryoballoon. The study aimed to establish the safety, efficacy, and feasibility of same day discharge for Cryoballoon PVI. Methods and results Multi-centre study across 12 centres. Procedural metrics, safety profile, and procedural efficacy of the PolarX Cryoballoon with the Arctic Front Advance (AFA) Cryoballoon were compared in a cohort large enough to provide definitive comparative data. A total of 1688 patients underwent PVI with cryoablation (50% PolarX and 50% AFA). Successful PVI was achieved with 1677 (99.3%) patients with 97.2% (n = 1641) performed as day case procedures with a complication rate of <1%. Safety, procedural metrics, and efficacy of the PolarX Cryoballoon were comparable with the AFA cohort. The PolarX Cryoballoon demonstrated a nadir temperature of −54.6 ± 7.6°C, temperature at 30 s of −38.6 ± 7.2°C, time to −40°C of 34.1 ± 13.7 s, and time to isolation of 49.8 ± 33.2 s. Independent predictors for achieving PVI included time to reach −40°C [odds ratio (OR) 1.34; P < 0.001] and nadir temperature (OR 1.24; P < 0.001) with an optimal cut-off of ≤34 s [area under the curve (AUC) 0.73; P < 0.001] and nadir temperature of ≤−54.0°C (AUC 0.71; P < 0.001), respectively.

Conclusions

This large-scale UK multi-centre study has shown that Cryoballoon PVI is a safe, effective day case procedure. PVI using the PolarX Cryoballoon was similarly safe and effective as the AFA Cryoballoon. The cryoablation metrics achieved with the PolarX Cryoballoon were different to that reported with the AFA Cryoballoon. Modified cryoablation targets are required when utilizing the PolarX Cryoballoon.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCryosurgeryPulmonary VeinsCatheter AblationHumansTreatment OutcomeTime FactorsUnited KingdomRecurrence

Stichwörter der Autor:innen

Atrial fibrillationCryoablationNovel technologyPulmonary vein isolation

Autor:innen und Institutionen

  • The Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS trust, W Smithfield, EC1A 7BE London, UK.
  • William Harvey Research Institute, Queen Mary University of London, London, UK.
  • Department of Electrophysiology, Royal Papworth Hospital, Cambridge, UK.
  • Department of Medicine, University of Cambridge, Cambridge, UK.
  • Department of Electrophysiology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
  • Department of Electrophysiology, Basildon and Thurrock University Hospital NHS Foundation Trust, Essex, UK.

ORCID-Profile: Shohreh Honarbakhsh, Joao Mesquita, Rahul Herlekar, Richard Till, Neil T Srinivasan, Fong Leong, Rajdip Dulai, Sandeep Panikker, John Paisey, Balasubramanian Ramgopal, Moloy Das, Jonathan Sahu, Mark J Earley, Malcolm C Finlay, Richard J Schilling, Ross J Hunter

Zitieren

APA

Honarbakhsh, S., Martin, C. A., Mesquita, J., Herlekar, R., Till, R., Srinivasan, N. T., Duncan, E., Leong, F., Dulai, R., Veasey, R., Panikker, S., Paisey, J., Ramgopal, B., Das, M., Ahmed, W., Sahu, J., Earley, M. J., Finlay, M. C., Schilling, R. J., & Hunter, R. J. (2023). Atrial fibrillation cryoablation is an effective day case treatment: the UK PolarX vs. Arctic Front Advance experience. Europace, 25(11). https://doi.org/10.1093/europace/euad286

Vancouver

Honarbakhsh S, Martin CA, Mesquita J, Herlekar R, Till R, Srinivasan NT, et al. Atrial fibrillation cryoablation is an effective day case treatment: the UK PolarX vs. Arctic Front Advance experience. Europace. 2023;25(11). doi:10.1093/europace/euad286

BibTeX
@article{Honarbakhsh2023,
  author = {Honarbakhsh, Shohreh and Martin, Claire A and Mesquita, Joao and Herlekar, Rahul and Till, Richard and Srinivasan, Neil T and Duncan, Edward and Leong, Fong and Dulai, Rajdip and Veasey, Rick and Panikker, Sandeep and Paisey, John and Ramgopal, Balasubramanian and Das, Moloy and Ahmed, Wissam and Sahu, Jonathan and Earley, Mark J and Finlay, Malcolm C and Schilling, Richard J and Hunter, Ross J},
  title = {Atrial fibrillation cryoablation is an effective day case treatment: the UK PolarX vs. Arctic Front Advance experience},
  journal = {Europace},
  year = {2023},
  volume = {25},
  number = {11},
  doi = {10.1093/europace/euad286}
}
Kostenlos starten →